Zindal

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zindal

Zindal: Classification and Identity of the Topical Antibiotic

Property Description
Active ingredient Clindamycin Phosphate
Form Topical Solution, Gel, or Foam
Pharmacological class Lincosamide Antibiotic
General Purpose Antibacterial and Anti-inflammatory
Origin Synthetic derivative

Zindal is a prescription-only topical preparation that contains the active ingredient Clindamycin Phosphate, and it is scientifically classified as a lincosamide antibiotic. This classification confirms that the medicine acts as an antibacterial agent intended for local application. The medicine's identity is rooted in its active component, which is a synthetic derivative of the parent compound Lincomycin. As a member of the lincosamide pharmacological class, Zindal is specifically formulated for topical use on the skin. The drug substance Clindamycin Phosphate requires prescription due to its potent activity and specific applications.


Composition and General Therapeutic Purpose

Zindal is typically prepared as a clear topical solution, gel, or foam, utilizing a specialized base such as a hydroalcoholic vehicle to ensure the active ingredient is delivered effectively into the skin. The medication is a single-ingredient product whose primary purpose is to leverage the unique properties of Clindamycin Phosphate. This compound operates as a prodrug, meaning it is chemically inactive until it is absorbed and converted into the biologically active Clindamycin upon application.

The general therapeutic goal of this preparation is two-fold: to provide local suppression of susceptible bacterial growth and to exert a distinct, associated anti-inflammatory effect. The use of topical clindamycin is characterized by this dual action, which targets inflammatory lesions. This dual benefit serves to address issues linked to superficial skin bacterial presence and the related inflammation.

Regulatory References

  1. NIH MedlinePlus Clindamycin Topical

What side effects are possible with Zindal?

Possible side effects and safety information

The safety profile of Zindal (topical clindamycin) is defined by both highly frequent local skin reactions and rare, serious systemic risks documented in regulatory labeling. The medicine's safety data is officially categorized across frequency and system-organ classes.


Documented Adverse Reaction Categories

Category Description (As per Regulatory Documentation)
Skin and Subcutaneous Tissue Disorders Localized effects, typically peaking in severity early in therapy.
Gastrointestinal Disorders Rare but serious systemic risks due to antibiotic absorption.

Officially Classified Side Effects

Very Common (ge 10% incidence) adverse reactions documented include dryness, oiliness, and erythema (redness). Reactions classified as Common (1-10% incidence) include peeling (desquamation), burning sensation, itching, and diarrhea. Local irritation may be observed to peak at approximately two weeks into treatment before decreasing.


Serious Adverse Reactions and Safety Restrictions

Topical use results in the systemic absorption of clindamycin, which leads to the rare but documented risk of colitis, including pseudomembranous colitis and bloody diarrhea. These serious gastrointestinal effects have been reported to occur up to several weeks following cessation of therapy.

Regulatory restrictions state that the medicine is contraindicated in individuals with a known history of hypersensitivity to clindamycin or lincomycin, or a history of specific bowel diseases such as regional enteritis or antibiotic-associated colitis. Furthermore, clindamycin has neuromuscular blocking properties, which may enhance the action of other neuromuscular blocking agents.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information states that topically applied clindamycin (Zindal) can be absorbed in sufficient amounts to produce systemic effects, which are the basis for overdose concerns.

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Overdose may result in systemic effects including diarrhea, abdominal cramps, and gastrointestinal disturbances. Accidental contact with the alcohol-based solution on eyes or mucous membranes may cause burning and irritation.
Physiological systems affected Primarily the gastrointestinal system due to the potential for colitis, including Pseudomembranous colitis.
Severity classification Systemic absorption has been associated with severe colitis which may result in patient death, acknowledging the risk of potentially fatal complications.
Emergency-response statements When significant or prolonged diarrhea occurs, the medicine should be discontinued immediately. Management of overdose is limited to general symptomatic and supportive measures. No specific antidote is cited in the regulatory documents.
When immediate medical help is required Individuals should seek emergency medical attention or call the poison control helpline right away for suspected overdose. Immediately call emergency services if the person has collapsed, is seizing, or has difficulty breathing.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by acknowledging the risk of systemic absorption from excessive topical use, which can lead to severe gastrointestinal complications typically associated with oral clindamycin. This risk mandates that individuals immediately seek emergency medical attention for severe presentations or suspected overdose. Official guidance focuses on symptomatic and supportive measures as the primary management strategy.

Therapeutic Uses of Zindal

What Zindal Treats: Main Uses and Benefits

Zindal (topical clindamycin) is used in situations involving certain distressing symptoms in dermatological contexts where specific symptoms cluster into patterns requiring antibacterial and anti-inflammatory support. This medication is commonly used to help control acne. It is primarily relevant in contexts marked by increased discomfort or tension where the patient seeks relief from visible, disruptive manifestations.


Treating Active Inflammatory Symptoms

This preparation is commonly used across conditions presenting with acute episodes, specifically mild-to-moderate acne vulgaris. It is used for managing symptom clusters that include the appearance of red, raised papules and pus-filled pustules. This medicine may be part of symptomatic management across conditions characterized by periods of heightened symptoms, such as acne vulgaris. The key benefit is that it may assist with reducing the overall symptom load related to the lesions, offering supportive relief during periods when symptoms become more noticeable.


Alleviating Redness and Localized Discomfort

Zindal is applied in scenarios where additional management of discomfort is required to control the inflammatory component. It is relevant for easing symptoms that interfere with daily comfort, helping to address challenging manifestations such as localized skin redness and swelling around the lesions. This action contributes to improved comfort during periods of heightened symptoms and helps improve day-to-day comfort by easing the symptomatic load of acute manifestations. It is commonly used in both adolescent and adult patients.

Quick Fact: Relief for Inflammatory Lesions Zindal is relevant for easing symptom clusters that include papules and pustules, assisting with maintaining comfort when symptoms intensify.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Zindal?

This section describes the official population eligibility and non-eligibility information as mandated by government regulatory bodies.


Eligibility Scope

Category Regulatory Status
Populations for whom use is allowed Adults and pediatric patients 12 years of age and older.
Populations for whom use is contraindicated Individuals with a history of hypersensitivity to clindamycin or lincomycin.
Condition-specific eligibility rules Contraindicated in individuals with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis.

Age-Related and Conditional Use

  • Age-related eligibility rules: Safety and effectiveness have not been established in pediatric patients under the age of 12. Clinical studies did not include sufficient subjects aged 65 and over to confirm differential responses.
  • Pregnancy and lactation eligibility status: Use during the first trimester of pregnancy is conditional, permitted only if clearly needed. Use during lactation is restricted; a decision must be made to discontinue nursing or discontinue the drug.
  • Eligibility-related restrictions: Use requires caution in atopic individuals and in patients receiving neuromuscular blocking agents.

Connection to the Overall Eligibility Profile

Official documents strictly define eligibility by formally prohibiting use based on a history of specific gastrointestinal diseases due to the risk of colitis. Eligibility is further structured by setting a strict minimum age threshold and applying explicit conditional use restrictions for special populations like nursing mothers and pregnant individuals.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zindal has a significant potential for drug interactions, primarily due to its effect on drug metabolism in the body. The drug is classified as an inhibitor of the major liver enzyme Cytochrome P450 3A (CYP3A) and the drug transporter P-glycoprotein (P-gp).

Clinically Significant Interactions

The co-administration of Zindal with other medicinal products that are sensitive substrates for CYP3A or P-gp can result in increased concentrations of those medicines in the blood. This increased exposure may heighten the risk of adverse reactions or toxicity from the co-administered drug. For certain combinations with narrow therapeutic indices, this interaction is considered a contraindication by regulatory authorities.

Conversely, co-administration with strong CYP3A inducers (medicines that increase the activity of the CYP3A enzyme) can cause a decrease in the concentration of Zindal itself, potentially reducing its effectiveness.

  • Interacting Categories: Strong inhibitors of CYP3A, strong inducers of CYP3A, and medicinal products that are sensitive substrates for CYP3A or P-gp.

  • Management: Management typically involves avoiding contraindicated combinations or adjusting the dosage of the co-administered medicine to maintain a safe and effective therapeutic range, though the specific dose changes are not detailed here.

Mechanism of Action

How Zindal Works: Mechanism of Action

Zindal’s activity is driven by a precise dual mechanism, focusing on suppression of susceptible bacterial proliferation and modulation of inflammatory mediators at the site of application.


Blocking Bacterial Protein Synthesis

The medicine acts as a prodrug, chemically inactive until converted by local phosphatase enzymes in the skin to active Clindamycin. This active molecule then targets and binds reversibly to the 50S ribosomal subunit of the bacterium, specifically the 23S rRNA component. This binding step inhibits the peptidyl transferase center, arresting the elongation of polypeptide chains and directly suppressing bacterial proliferation (bacteriostasis).


Modulation of Local Inflammatory Mediators

This secondary physiological effect on processes related to inflammation arises from the drug’s mechanism. By reducing the overall microbial load, the drug inherently limits the secretion of bacterial pro-inflammatory enzymes (like lipases) and toxins. Furthermore, Clindamycin directly modulates host immune activity by interfering with processes like neutrophil chemotaxis and superoxide production. These actions collectively limit the downstream signaling that drives localized inflammatory responses in the affected tissue.


Mechanistic Constraints and Functional Limitations

The mechanism is subject to bacterial resistance, typically through ribosomal methylation mediated by the erm gene, which changes the binding site on the 50S subunit. Efficacy relies completely on the necessary enzymatic hydrolysis of the prodrug to achieve the active concentration required for both ribosomal and anti-inflammatory actions.

Dosage and Administration Information

Zindal is a topical medicine intended for external application only, available in authorized preparations such as solutions, gels, lotions, foams, and single-use pledgets. The route of administration is strictly cutaneous.

Usage is standardized for adults and adolescents 12 years of age and older, as its use has not been established for younger pediatric patients. The official prescribed dose is a "thin film" lightly applied to the affected area. Depending on the specific formulation type, Zindal is administered either once or twice daily.

To ensure proper use, the skin must be thoroughly washed with a mild soap and dried before each application.

Official Administration Rule Procedural Requirement
Dosing Application Apply a thin film to the entire area affected by the condition, not just individual lesions.
Sensitive Area Contact Avoid contact with eyes, mouth, and mucous membranes; rinse with water immediately if contact occurs.
Lotion/Foam Handling The lotion form must be shaken well before use; foam preparations are considered flammable and must be kept away from heat or open flame.
Missed Timing If a scheduled application is missed, it should be applied as soon as remembered, unless it is nearly time for the next dose; two doses must not be applied simultaneously.

The administration protocol defines an extended course of therapy, often requiring several continuous weeks to assess the full effect. This structured approach to application ensures consistency in usage.

Recent Clinical Evidence

Research evidence / Overview of studies for Zindal (Topical Clindamycin)

This section provides an objective overview of the clinical research conducted on Zindal (topical clindamycin), summarizing the types of studies, the populations examined, and the evidence limitations, without offering clinical advice or efficacy claims.


Evidence for Use in Mild-to-Moderate Acne Vulgaris

The main research exploring Zindal focused on its evaluation in mild-to-moderate acne vulgaris. The foundational evidence was gathered through Randomized Controlled Trials (RCTs). In these trials, researchers examined the drug against an inactive substance, known as the vehicle or placebo, to monitor specific measurements related to lesion characteristics and severity. Studies were conducted during periods of increased symptom activity and often involved adolescents and adults with specific levels of acne severity.

What remains uncertain is the durability of these observed patterns. Follow-up durations were typically limited to 8 to 16 weeks in the core efficacy trials. While these study results reflect the specific conditions under which they were conducted, there is limited information for long-term outcomes, meaning long-term patterns of change beyond this intermediate period are not fully established.


Comparison of Monotherapy versus Combination Therapy Studies

Research has also explored how Zindal used alone (monotherapy) was evaluated against Zindal in combination with other topical agents, such as benzoyl peroxide. These comparative studies were used to evaluate different approaches, recording lesion counts and microbial changes for both single-agent and multiple-agent treatment groups. The research base highlights the recognized emergence of antibiotic resistance in C. acnes strains during the use of topical clindamycin monotherapy; this issue means that the long-term effectiveness of monotherapy is a specific area of uncertainty.

Frequently Asked Questions (FAQ)

Common questions about Zindal (FAQ)


Q: Is Zindal the same kind of medicine as [similar drug name]?

A: Zindal contains the active ingredient Clindamycin Phosphate, which belongs to a class of antibiotics known as lincosamides. This classification defines the drug's type and how it works. Official documents provide Zindal's classification but do not offer direct comparisons to specific competing brands or medications.


Q: Why do people say they feel better immediately, even though the text says Zindal takes longer to work?

A: While the full clinical effect of Zindal takes several continuous weeks to assess, some of the initial, common local skin reactions, such as dryness or irritation, are reported to peak at about two weeks and then decrease. A decline in local side effects after the initial two weeks may be perceived by some users as an immediate improvement in their condition.


Q: Can older adults safely use Zindal?

A: Official regulatory documents indicate that clinical studies did not include enough subjects aged 65 and over to fully determine if they respond differently than younger patients. Therefore, caution is advised when extrapolating safety data to this population.


Q: How long does Zindal stay in your system after the last dose?

A: After topical application, only minimal amounts of the active ingredient are absorbed into the bloodstream and cleared relatively quickly. However, serious, though rare, systemic effects, such as colitis, have been reported in the weeks following discontinuation of therapy.


Q: Can Zindal affect fertility or conception?

A: Non-clinical animal studies related to fertility showed no evidence of reproductive toxicity or impairment of fertility. Information in the regulatory documents on specific effects on human fertility or conception is limited.


Q: Does Zindal have a 'black box' warning, and what does that mean?

A: The regulatory label includes a significant Warning regarding the potential for systemic absorption resulting in severe colitis, including pseudomembranous colitis. This is a serious safety risk noted in the label’s Warnings section, related to the potential for systemic absorption.


Q: Is it common to feel a little anxious when starting Zindal?

A: The official product information does not list anxiety, mood changes, or other mental health effects among the commonly reported side effects observed in clinical trials.


Q: Are there any long-term side effects associated with Zindal use?

A: The core clinical trials for Zindal were limited to intermediate timeframes, typically lasting 8 to 16 weeks. Consequently, safety patterns and long-term outcomes extending beyond this period are not fully established in the core research evidence.


Q: What is the mechanism of action that makes Zindal effective?

A: Zindal is converted into active Clindamycin upon application. This active component suppresses bacterial growth by interfering with protein synthesis and also helps reduce local inflammation.


Q: Does Zindal cause weight gain or loss?

A: Weight gain is not listed among the documented adverse reactions. However, unusual weight loss has been noted as a rare systemic adverse reaction associated with clindamycin use.


Q: Is Zindal considered a long-term or short-term treatment?

A: Official documents suggest Zindal is intended for an extended course of therapy, often requiring several continuous weeks of application to assess its full effect.


Q: Why do people sometimes say Zindal 'stopped working' for them?

A: The effectiveness of Zindal may be affected by the emergence of antibiotic resistance in the target bacteria. Official documents recognize that this development of resistance is a concern, particularly when Zindal is used as monotherapy (alone).


Q: Why is Zindal not recommended for children?

A: The safety and effectiveness of Zindal have not been established in pediatric patients under the age of 12. Its use is officially allowed for adolescents aged 12 years and older.


Q: Does Zindal interact with alcohol?

A: The solution and foam formulations of Zindal contain an alcohol base which is flammable and can cause local skin irritation. There is no specified systemic drug-alcohol interaction noted in the regulatory documents.


Q: Can Zindal affect my mood or mental health?

A: Effects on mood or mental health are not listed among the commonly reported side effects documented in clinical trials.


Q: Can Zindal be split or crushed, or must it be swallowed whole?

A: Zindal is a topical preparation, meaning it is only to be applied externally to the skin (as a solution, gel, or foam). It is not designed to be swallowed, split, or crushed.


Q: How common is resistance to Zindal over time?

A: The regulatory label indicates that the development of antibiotic resistance is a recognized factor, particularly when Zindal is used alone (monotherapy). Specific rates of resistance over time are not provided in the official information.


Q: How to Store and Dispose of Zindal?

A: Zindal should be stored at Controlled Room Temperature (between 20 C and 25 C) and protected from freezing. Due to the flammable nature of some forms, it must be kept away from heat, fire, and flame. Unused medication should be disposed of according to local environmental guidelines.

How should Zindal be stored and disposed of?

How to Store and Dispose of Zindal

Official regulatory documentation requires Zindal (Clindamycin Phosphate Topical) to be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from freezing and excessive heat.

Required Handling

Due to the flammable nature of the vehicle in the solution and foam, the product must be kept away from heat, fire, flame, and smoking. The container should be kept tightly closed when not in use.

Child Safety and Disposal

Zindal must be stored out of the reach of children and pets. Unused or expired medication should be discarded according to local regulations. Regulatory guidance recommends using a drug take-back program or mixing the product with an unappealing substance, and it advises against disposing of the medicine down a drain or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zindal found in:

A-Z Index: